Discovery of Biomarkers Predictive of GSI Response in Triple-Negative Breast Cancer and Adenoid Cystic CarcinomaAlexander Stoeck, Sriram Sathyanarayanan, Stephen E. Fawell et al.|Cancer Discovery|2014Cited by 154
Inhibition of Notch Signaling in Combination with Paclitaxel Reduces Platinum-Resistant Ovarian Tumor GrowthJolijn W. Groeneweg, Bo R. Rueda, Celeste M. DiGloria et al.|Frontiers in Oncology|2014Cited by 59
Combination of the mTOR Inhibitor Ridaforolimus and the Anti-IGF1R Monoclonal Antibody Dalotuzumab: Preclinical Characterization and Phase I Clinical TrialSerena Di Cosimo, José Baselga, Sriram Sathyanarayanan et al.|Clinical Cancer Research|2014Cited by 56
Abstract 1868: Response biomarkers to IGF1R and mTOR inhibitor combination therapy in ovarian carcinomaBrian B. Haines, Sriram Sathyanarayanan, Michael J. Wick et al.|Cancer Research|2012Cited by 1
Supplementary Figure 4 from Combination of the mTOR Inhibitor Ridaforolimus and the Anti-IGF1R Monoclonal Antibody Dalotuzumab: Preclinical Characterization and Phase I Clinical TrialSerena Di Cosimo, José Baselga, Sriram Sathyanarayanan et al.|Unknown|2023Cited by 0